Dihexa

Background

Dihexa (chemical name often given as N‑hexanoic‑Tyr‑Ile‑(6)‑aminohexanoic amide) is a synthetic angiotensin IV (Ang IV) analog developed as a metabolically stabilized, brain‑penetrant peptide derivative with putative procognitive and neuroprotective properties.[3][1] It is also referenced in the literature and patent landscape as PNB‑0408.[1] Dihexa emerged from structure–activity optimization programs seeking longer‑acting Ang IV analogs that retained or enhanced the memory‑facilitating effects observed after central Ang IV administration in rodents.[3]

Ang IV (Val‑Tyr‑Ile‑His‑Pro‑Phe) is a hexapeptide fragment of angiotensin II identified approximately three decades ago as a modulator of learning and memory when administered intracerebroventricularly in rats.[3] Multiple metabolically stabilized Ang IV analogs were generated to overcome rapid degradation and limited oral bioavailability of the native peptide. Dihexa is among these next‑generation analogs and has been described in preclinical work as highly lipophilic with robust central nervous system (CNS) penetration after systemic administration.[3]

As of the latest published data, Dihexa/PNB‑0408 remains an experimental compound under preclinical development and is not approved as a drug for any indication in the United States or European Union.[1][3]

Mechanism of action

Relationship to angiotensin IV and IRAP

Ang IV and its analogs have been proposed to act primarily through inhibition of insulin‑regulated aminopeptidase (IRAP), also known as AT4 receptor, though the receptor concept has evolved.[3] In 2001, IRAP was identified as a high‑affinity binding site for Ang IV, and subsequent work has explored Ang IV analogs as IRAP inhibitors with potential cognitive benefits.[3]

Dihexa is structurally derived from Ang IV but modified to enhance metabolic stability and CNS availability.[3] While Dihexa itself is not extensively profiled in the IRAP enzymology literature, it is generally classified within the metabolically stabilized Ang IV analogs/peptidomimetics targeting IRAP as a key molecular mechanism.[3] IRAP inhibition is thought to increase the local availability of neuropeptides such as vasopressin and oxytocin and to affect trafficking of GLUT4 and other substrates, which may influence synaptic plasticity and cognitive function.[3]

Alternative or additional mechanisms

Beyond IRAP, Ang IV analogs have been reported to engage other pathways, and several mechanistic hypotheses remain under investigation:

• Modulation of neurotrophic signaling and synaptic plasticity pathways relevant to learning and memory (e.g., effects on hippocampal long‑term potentiation), mainly inferred from Ang IV and related analogs rather than Dihexa specifically.[3]
• Possible actions on cerebral blood flow, neuroinflammation, and mitochondrial function, extrapolated from broader renin–angiotensin system (RAS) biology and neurodegeneration models.[5]

Evidence regarding direct binding of Dihexa to classical angiotensin receptors (AT1, AT2) is limited in the published, peer‑reviewed literature. Available reviews group Dihexa with Ang IV‑based IRAP‑targeted peptidomimetics, and the detailed receptor pharmacology of Dihexa remains incompletely characterized in open sources.[3]

Overall, the leading mechanistic framework is that Dihexa is a brain‑penetrant Ang IV analog acting primarily as an IRAP inhibitor, with downstream effects on neuropeptide metabolism, synaptic plasticity, and cognition, but this remains based largely on preclinical and indirect evidence.[3]

Evidence summary

Preclinical data

Published preclinical evidence for Dihexa/PNB‑0408 is relatively sparse and consists mainly of animal models of neurodegeneration:

1. 3‑Nitropropionic acid (3‑NP)–induced Huntington’s disease‑like model (rats) – Effects of an Angiotensin IV Analog on 3‑Nitropropionic Acid‑Induced Huntington’s Disease‑Like Symptoms in Rats (Journal of Huntington’s Disease, 2023).[1]

   • Design: 40 male Wistar rats randomized into three groups: vehicle, 3‑NP, and 3‑NP + PNB‑0408.[1]
   • Intervention: Chronic 3‑NP exposure to induce Huntington’s disease (HD)–like pathology; PNB‑0408 administered concurrently (route and dose not fully detailed in the abstract).[1]
   • Outcomes: Body weight, motor function, spatial learning, and memory assessed over 5 weeks, followed by histopathology.[1]
   • Key findings: 3‑NP produced reduced weight gain, impaired spatial learning/memory, and motor dysfunction.[1] PNB‑0408 did not significantly protect against 3‑NP–induced behavioral impairments or neuropathology under the tested conditions.[1] The authors concluded that, despite prior positive findings in other neurodegenerative models (Alzheimer’s, Parkinson’s disease models, described in the introduction), PNB‑0408 showed no clear neuroprotective effect in this HD model.[1]

2. Alzheimer’s and Parkinson’s disease models (indirect) – The Huntington’s study cites earlier, non‑Huntington’s work in animal models of Alzheimer’s disease and Parkinson’s disease where PNB‑0408 reportedly demonstrated neuroprotective and procognitive properties.[1] At present, those primary data are not readily accessible in major indexed repositories, and peer‑reviewed detail on Dihexa’s performance in those models is limited. The available review on Ang IV analogs notes that several metabolically stabilized analogs, including Dihexa, improved performance in rodent memory tasks and were engineered for prolonged activity.[3]

3. Ang IV analog series studies – A recent medicinal chemistry study of metabolically stabilized Ang IV analogs evaluated structure‑activity relationships and pro‑cognitive potential; it confirmed that Ang IV analogs can be optimized for in vitro IRAP inhibition and in vivo cognitive effects in rodents, although individual performance of Dihexa is not always isolated in public summaries.[2][3]

Overall, preclinical evidence for Dihexa is limited, mixed, and largely model‑specific, with at least one negative study in an HD‑like model and indirect support from older Alzheimer’s/Parkinson’s models.

Human data

No clinical trials of Dihexa/PNB‑0408 in humans were identified in ClinicalTrials.gov or other major trial registries, and there are no peer‑reviewed human pharmacokinetic, safety, or efficacy studies available to date.[3][1] Consequently, all efficacy and safety inferences are based on animal models and mechanistic considerations.

Clinical and research uses

Approved indications

Dihexa is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any indication.

• FDA databases and label repositories do not list Dihexa or PNB‑0408 as an approved drug substance.[4][7]
• EMA public assessment reports likewise do not list Dihexa.[7]

Investigational and experimental uses

In the peer‑reviewed literature, Dihexa/PNB‑0408 appears primarily as a preclinical research tool in:

• Neurodegenerative disease models, including Huntington’s disease‑like pathology induced by 3‑NP.[1]
• Cited (but not fully detailed) models of Alzheimer’s disease and Parkinson’s disease where it is described as neuroprotective and procognitive.[1]
• Broader reviews of Ang IV/IRAP‑targeted compounds as potential antidementia agents and cognitive enhancers.[2][3]

There is no registered clinical development program with publicly posted phase 1–3 trials for Dihexa at this time.

Off‑label and non‑regulated use

Some non‑peer‑reviewed sources (e.g., commercial peptide vendors, anecdotal reports) have promoted Dihexa as a nootropic. These sources are not supported by controlled human data and are outside the scope of rigorous medical evidence. No dosing, safety, or efficacy claims from such sources can be validated here.

Dosing context

Because Dihexa has not entered formal human trials, there is no clinically established dosing regimen.

In animal studies, dosing has been formulated solely for experimental purposes:

• In the 3‑NP Huntington’s disease‑like rat study, PNB‑0408 was administered chronically along with 3‑NP for 5 weeks, but the publicly available abstract does not specify the exact dose, route, or frequency; these parameters are detailed in the full article.[1]
• Earlier Ang IV analog work often used intracerebroventricular or systemic administrations at microgram to milligram per kilogram doses in rodents to test cognitive endpoints; Dihexa was designed to be more lipophilic to allow systemic administration with CNS penetration.[3]

Any dosing reported in non‑peer‑reviewed or non‑regulatory sources should not be considered evidence‑based. Dihexa remains an investigational preclinical compound, and no dosage can be regarded as clinically validated.

Safety profile

Preclinical safety observations

The available peer‑reviewed literature offers limited information on Dihexa’s safety and toxicity:

• In the 3‑NP Huntington’s disease‑like rat study, the primary focus was on neurobehavioral outcomes; major overt toxicities attributable to PNB‑0408 were not highlighted in the abstract.[1] However, detailed toxicologic assessments (e.g., organ histopathology beyond brain, clinical chemistry, cardiovascular parameters) were not the central aim and are not comprehensively reported.
• Reviews of Ang IV analogs and IRAP inhibitors suggest that such compounds can be administered to rodents over days to weeks with acceptable tolerability, but systematic toxicity profiling (e.g., GLP toxicology, reproductive toxicity, carcinogenicity) for Dihexa has not been published.[3]

Human safety data

There are no human safety data for Dihexa in:

• Controlled clinical trials.
• Formal case series or pharmacovigilance databases.

Consequently, potential risks must be regarded as unknown. Possible areas of concern, extrapolated from mechanism and RAS involvement, could include:

• Effects on blood pressure and vascular regulation, given Ang IV’s origin within the renin–angiotensin system.[5]
• Effects on glucose metabolism and insulin signaling, due to IRAP’s role in GLUT4 trafficking.[3]
• CNS effects related to modulation of neuropeptide levels and synaptic plasticity.

However, these concerns are hypothetical and not yet characterized for Dihexa specifically.

Adverse effects and contraindications

• No characterized adverse effect profile is available for Dihexa in humans.
• No formal contraindications have been defined because the compound has not progressed to regulatory assessment.

Any discussion of side effects or contraindications in non‑scientific sources is speculative and not supported by peer‑reviewed evidence.

Regulatory status

As of the most recent accessible data:

• United States (FDA)

  • Dihexa/PNB‑0408 is not listed as an approved drug in FDA’s databases or product labels.[4][7]
  • There are no publicly available FDA approval documents, labeling, or advisory committee materials referencing Dihexa.

• European Union (EMA)

  • Dihexa is not included in EMA’s database of authorized medicinal products.[7]
  • No centralized or national EU approvals have been reported in peer‑reviewed sources.

• Clinical trial registries

  • A search of ClinicalTrials.gov and other large registries shows no registered interventional studies of Dihexa/PNB‑0408 in humans.[3]

Accordingly, Dihexa should be regarded as an unapproved, preclinical Ang IV analog under investigation in animal models, with no current recognized medicinal product status in the US or EU.